Effect of a specific and selective A$_{2B}$ adenosine receptor antagonist on adenosine agonist, AMP and allergen-induced airway responsiveness and cellular influx in a mouse model of asthma

S. Jamal Mustafa, Ahmed Nadeem, Ming Fan, Hongyan Zhong, Luiz Belardinelli and Dewan Zeng

Department of Physiology and Pharmacology, School of Medicine, West Virginia University (SJM, AN), Morgantown, WV; Department of Pharmacology, East Carolina University (MF), Greenville, NC; CV Therapeutics, Inc. (HZ, LB, DZ), Palo Alto, CA
Running Title Page

Running Head: CVT-6883 inhibits airway reactivity and inflammation

Correspondence:

*Dr. S. Jamal Mustafa

West Virginia University

Morgantown, WV 26505-9229

Email: smustafa@hsc.wvu.edu

Telephone: 304-293-5830

Fax: 304-293-7038

No. of text pages: 17

No. of tables: 0

No. of figures: 4

No. of references: 33

No. of words in abstract: 250

No. of words in introduction: 655

No. of words in discussion: 1253


Section: Pulmonary
Abstract

It has been previously proposed that adenosine plays an important role in the pathogenesis of asthma. The proposed mechanism of action for nucleoside adenosine is to activate A2B adenosine receptors (AR) and to indirectly modulate levels of mediators in the lung. In vivo data supporting the role of A2BAR in airway reactivity and inflammation in allergic animal models are lacking. The present study describes the effects of a selective A2BAR antagonist, CVT-6883, on airway reactivity and inflammation in an allergic mouse model of asthma. Mice were sensitized with ragweed (i.p.) on days 1 and 6 and challenged with 0.5% ragweed on days 11, 12 and 13. On day 14, airway reactivity to 5'-N-ethylcarboxamidoadenosine (NECA), adenosine 5'-monophosphate (AMP) or allergen challenge was measured in terms of enhanced pause (Penh). Aerosolized NECA elicited concentration-dependent increases in Penh, which were significantly attenuated by CVT-6883 (0.4, 1.0 or 2.5 mg/kg, i.p.). Aerosolized AMP elicited significant increases in Penh in sensitized mice and the effect was significantly attenuated by either CVT-6883 (1 mg/kg, i.p.) or montelukast (1 mg/kg, i.p.). Allergen challenge induced late allergic response (LAR) in sensitized mice, which was inhibited by CVT-6883 (1 mg/kg, i.p.). Allergen challenge also increased the number of cells in BALF obtained from sensitized mice, and that was reduced by either CVT-6883 (6 mg/ml aerosolization for 5 min) or theophylline (36 mg/ml aerosolization for 5 min). These results suggest that A2BAR antagonism plays an important role in inhibition of airway reactivity and inflammation in this model of allergic asthma.
Introduction

Evidence for the potential role of adenosine in the pathogenesis of asthma has been growing steadily since the early observation of its bronchoconstrictor effect in human asthmatics. In the early 1980s, it was shown that adenosine or AMP (which is converted to adenosine in vivo by 5'-nucleotidase) induces bronchoconstriction in asthmatics but not in normal subjects (Cushley et al., 1983). In contrast to methacholine, which induces changes in airway caliber, AMP-induced bronchial hyperresponsiveness (BHR) is proposed to be related to the inflammatory status of the asthmatic lung (Spicuzza L et al., 2003). Adenosine has also been shown to increase the concentrations of mediators released from mast cells, such as histamine, tryptase, LTC₄ and PDG₂ (Crimi et al, 1997). Adenosine-induced bronchoconstriction is attenuated by drugs that either inhibit mast cell activation or serve as antagonists to the mediators released from the mast cells (Holgate, 2005). Thus, a potential mechanism by which adenosine causes bronchoconstriction is mast cell activation (Polosa et al., 2002; Holgate, 2005). In addition, it has been shown that the concentration of adenosine in the bronchoalveolar lavage fluid (BALF) of patients with asthma is higher than that in non-asthmatics (Driver et al. 1993). Higher concentrations of adenosine were detected in the exhaled breath condensate of atopic asthmatics as compared to those of nonatopic controls (Huszar et al., 2002). Hence, adenosine may function as a paracrine mediator of the inflammatory responses in the lung.

The effects of adenosine are mediated through a family of cell surface G-protein coupled receptors, which are currently classified into four adenosine receptor subtypes: A₁, A₂A, A₂B, and A₃. The roles of A₁ and A₂A ARs in the cardiovascular system have
been well established (Shryock and Belardinelli, 1997), whereas the role of A3 AR is less well understood. For the A2B AR, recent studies have suggested that the A2B AR may play an important role in mediating airway reactivity and modulating chronic inflammatory responses in the lung. For example, adenosine, via activation of A2B AR, increases the release of inflammatory cytokines such as IL-4, IL-8 and IL-13 from human mast cells (HMC-1) (Feoktistov and Biaggioni, 1995; Feoktistov et al., 2001; Ryzhov et al., 2004) and these cytokines can induce IgE synthesis by B lymphocytes (Ryzhov et al., 2004). Similarly, adenosine activation of A2B AR increases the release of inflammatory cytokines from human bronchial smooth muscle cells, human lung fibroblasts, and human airway epithelial cells (Zhong et al., 2004; Zhong et al., 2005). These cytokines, in turn, induce differentiation of lung fibroblasts into myofibroblasts (Zhong et al., 2005) and, increase the release of TNFα from monocytes (Zhong et al., 2006). These effects of adenosine have been shown to be inhibited by selective antagonists of the A2B AR (Feoktistov and Biaggioni, 1995; Feoktistov et al., 2001; Ryzhov et al., 2004; Zhong et al., 2004; Zhong et al., 2005; Zhong et al., 2006). Thus, A2B ARs may play an important role in the pathophysiology of asthma.

The allergic mouse model developed and characterized in this laboratory has been used to further understand the role of adenosine and its receptors in airway reactivity and inflammatory (Fan and Mustafa, 2002; Fan and Mustafa, 2006). The previously described features of this model are: 1) aerosolized adenosine causes a concentration-dependent bronchoconstriction, measured as Penh in sensitized mice; and 2) aerosolized adenosine potentiates the allergen-induced airway inflammation and both of these effects are
blocked by theophylline at therapeutic concentrations (Fan and Mustafa, 2002; Fan and Mustafa, 2006).

CVT-6883 is a specific and selective antagonist to the A_{2B} AR. Its binding affinities for the four subtypes of ARs were determined using competition radioligand binding assays in membranes isolated from cell lines that over-express each of the four ARs (Sun et al, 2006). The aims of this study were to determine the effect of CVT-6883: 1) on the airway reactivity induced by aerosolized NECA, AMP or allergen and 2) on the numbers of inflammatory cells in BALF after allergen challenge.
Methods

Animals

Male BALB/c mice, 6 to 8 wk of age and free of specific pathogens, were obtained from Harlan Laboratories (Indianapolis, IN). The animals were maintained on a ragweed-free diet. All experimental animals used in this study were under an approved protocol from the Institutional Animal Care and Use Committee of East Carolina University.

Chemicals and Reagents

Ragweed pollen extract was purchased from Greer Laboratories (Lenoir, NC). Imject<sup>®</sup> Alum was purchased from Pierce Laboratories (Rockford, IL). Theophylline was purchased from Sigma Chemical Co. (St. Louis, MO) and montelukast sodium was a gift from Merck & Co., Inc. (PA). NECA (5′-N-ethylcarboxamidoadenosine) was purchased from Sigma Chemical (St. Louis, MO). Diff-Quik stain set was purchased from Dale Behring Inc. (Newark, DE).

CVT-6883 was synthesized and provided by CV Therapeutics, Inc. (Palo Alto, CA). For i.p. injection, CVT-6883 was dissolved in DMSO and diluted in saline and thus the i.p. vehicle of CVT-6883 is DMSO/saline (25/75, v/v).

Experimental Protocols

Sensitization and challenge with ragweed

Sensitization and challenge with ragweed (SENS) or saline (control) were performed according to a method described previously (Fan and Mustafa, 2002; Fan and Mustafa, 2006).
Measurement of airway reactivity

On Day 14, mice were challenged with NECA, AMP or allergen and the airway reactivity was measured using barometric plethysmography (Fan and Mustafa, 2002; Oldenburg and Mustafa, 2005, Fan and Mustafa, 2006). It has been previously shown that changes (increases or decreases) in Penh correlate with changes (increases or decreases) in airway resistance in this model (Justice et al., 2001).

NECA challenge

Mice sensitized and challenged with ragweed (SENS) were used in this study. There were four treatment groups: vehicle (DMSO/saline, 25/75, v/v, i.p.) and three concentrations of CVT-6883 treated groups (0.4 mg/kg, 1.0 mg/kg and 2.5 mg/kg, i.p.). On day 14, CVT-6883 or vehicle was given by i.p. injection fifteen minutes prior to NECA challenge. NECA was dissolved in ethanol and diluted in saline, and thus the final NECA solution contained ethanol/saline (10/90, v/v). For NECA challenge, mice were placed in the Plexiglas chambers and exposed to the nebulization vehicle (ethanol/saline, 10/90, v/v) or increasing concentrations of NECA (46.9, 93.8, 187.5 and 375.0 µg/ml) for 2 min with Buxco Aerosol Delivery System (Version 1.5, Sharon, CT) at 2.5 L/min of the dilution flow and 0.15 L/min of the trickle flow. Recordings of pressure fluctuations in the chamber were taken for 5 min following each nebulization. The next concentration of NECA was not given until the Penh values returned to baseline values. Airway reactivity was expressed as percentage increase in Penh compared to Penh values from the nebulization vehicle (ethanol/saline, 10/90, v/v).
AMP challenge

Both control mice (control, sensitized and challenged with saline) and sensitized mice (SENS, sensitized and challenged with ragweed) were used in this study. There were six groups of animals: control mice treated with the vehicle (DMSO/saline, 25/75, v/v, i.p.), CVT-6883 (1 mg/kg, i.p.) or montelukast (1 mg/kg, i.p.) and sensitized mice treated with the vehicle (DMSO/saline, 25/75, v/v, i.p.), CVT-6883 (1 mg/kg, i.p.) or montelukast (1 mg/kg, i.p.). On day 14, the vehicle, CVT-6883, or montelukast was given fifteen minutes prior to AMP challenge. AMP was dissolved in saline. For AMP challenge, mice were placed in the Plexiglas chambers and exposed to the nebulization vehicle (saline) or increasing concentrations of AMP (6, 12 and 24 mg/ml in saline) for 2 min. The remaining procedure was same as described above for NECA challenge. Airway reactivity was expressed as percentage increase in Penh compared to the nebulization vehicle (saline).

Allergen challenge: airway reactivity

Both control mice (control, sensitized and challenged with saline) and sensitized mice (SENS, sensitized and challenged with ragweed) were used in this study. There were three groups: control mice treated with the vehicle (DMSO/saline, 25/75, v/v), sensitized mice treated with the vehicle or CVT-6883 (1 mg/kg, i.p.). On day 14, the vehicle or CVT-6883 was given 60 min prior to allergen challenge. For allergen challenge, mice were placed in Plexiglas chambers and exposed to either 5% of ragweed or saline for 10 min with a DeVilbiss nebulizer (Somerset, PA) at 2.0 ml/min and the aerosol particles had a median aerodynamic diameter of less than 4 µm. Penh was recorded for 5 h with
every 5 min interval. Late allergic response (LAR) was calculated using the area under the curve (AUC₃₋₄h).

**Allergen challenge: inflammatory cells in the bronchoalveolar lavage fluid (BALF)**

Both control mice (control, sensitized and challenged with saline) and sensitized mice (SENS, sensitized and challenged with ragweed) were used in this study. There were four groups: control mice or sensitized mice treated with the vehicle, CVT-6883 (6 mg/ml, aerosol for 5 min) or theophylline (36 mg/ml, aerosol for 5 min). The dose of theophylline was chosen based on our previous work (Fan and Mustafa, 2002) and the dose of CVT-6883, 6 mg/ml, was the highest soluble concentration in the vehicle. On day 14, fifteen minutes after administration of CVT-6883 or theophylline, mice were exposed to either 2% of ragweed or saline for 10 min with a DeVilbiss nebulizer (Somerset, PA) at 2.0 ml/min and the aerosol particles had a median aerodynamic diameter of less than 4 µm.

Five hours after the allergen challenge, BALF were collected and analyzed to assess airway inflammation. Mice were killed using i.p. injection of 0.1 ml pentobarbitone sodium (200 mg/ml). The trachea was cannulated to introduce 0.8 ml phosphate-buffered saline (PBS) into the lungs three times, followed by centrifugation at 1500 rpm for 6 min at 4°C (Beckman®, Model TJ-6 centrifuge). After removing the supernatant, the BALF cells were re-suspended in 1 ml of PBS. The total cells were then counted manually in a hemocytometer chamber. Cells were spun onto glass slides (Cytospin 3, Cytospin, Shandon, UK), air dried, fixed with methanol and stained with Diff-Quik stain set (Dale Behring Inc. Newark, DE). A differential count of at least 300 cells was made according
to standard morphologic criteria. The number of cells recovered per mouse were calculated and expressed as mean ± SEM/ml for each group.

**Statistical Analysis**

Data are expressed as mean ± SEM. Data were analyzed by Analysis of variance (ANOVA) followed by Tukey’s test for multiple comparisons. Paired t-test was utilized for calculating difference in Penh values before and after different drug treatments. A $p$ value of <0.05 was considered statistically significant.

**Results**

**Effect of CVT-6883 on NECA-induced Increases in Penh**

The effect of CVT-6883 on NECA-induced airway reactivity in mice that were sensitized and challenged with ragweed (SENS) was determined. As shown in Figure 1, aerosolized NECA increased Penh values in a concentration-dependent manner. The Increases in Penh (% of nebulization vehicle) induced by NECA (46.9, 93.8, 187.5 and 375.0 µg/ml) were 86.00 ± 9.07, 136.38 ± 18.42, 200.48 ± 13.37 and 340.66 ± 46.64%, respectively (n = 6).

Treatment with CVT-6883 (0.4, 1.0 or 2.5 mg/kg, i.p.,15 min prior to NECA challenge) attenuated the NECA-induced increases in Penh. At all four concentrations of NECA tested, the increases in Penh in the vehicle-treated group were significantly greater than the increases in Penh in the CVT-6883-treated groups ($p < 0.05$, ANOVA), except there was no statistical difference between vehicle- and the high dose of CVT-6883 (2.5 mg/kg)-treated groups at the NECA concentration of 93.8 µg/ml (Fig. 1).
There was no significant difference among the baseline Penh values of the four groups (p > 0.05, ANOVA). In addition, there was no significant difference in Penh values before and after injection of the vehicle or CVT-6883 (p > 0.05, paired t-test). This indicates that CVT-6883 treatment alone did not affect the airway reactivity.

Effects of CVT-6883 and Montelukast on AMP-induced Penh Increase

The effects of CVT-6883 and montelukast on AMP-induced airway reactivity were determined. As shown in Figure 2, aerosolized AMP increased Penh values in a concentration-dependent manner in mice that were sensitized and challenged with ragweed (SENS) (Fig. 2b) but not in mice that were sensitized and challenged with saline (control) (Fig. 2a).

In sensitized mice that were treated with vehicle, the increases in Penh (% of nebulization vehicle) induced by AMP (6, 12 and 24 mg/ml) were 116.60 ± 13.41, 180.68 ± 34.93 and 561.49 ± 269.93%, respectively (n = 8). Treatment (15 min prior to AMP challenge) with either CVT-6883 (1 mg/kg, i.p.) or montelukast (1 mg/kg, i.p.) attenuated the AMP-induced increases in Penh. The AMP-induced increases in Penh in the SENS+vehicle group was significantly greater than increases in Penh in SENS+CVT-6883 group (12 and 24 mg/ml AMP) or SENS+montelukast group (6, 12, and 24 mg/ml AMP) (p < 0.05, ANOVA).

Effect of CVT-6883 on Late Allergic Response

The effect of CVT-6883 on the airway reactivity induced by allergen in the SENS mice was also determined. As shown in Figure 3 (a), late allergic response to allergen challenge was observed in sensitized but not in control mice. Treatment (60 min prior to
allergen challenge) with CVT-6883 (1 mg/kg, i.p.) attenuated this late allergic response (Fig. 3a, top panel).

To quantify this late allergic response, the area under the Penh-time curve (AUC) was calculated for the whole 5 h period as well as for late allergic response that occurred between 3-4 h after allergen challenge. The percent (%) increases in AUC_{3-4h} for SENS+vehicle and SENS+CVT-6883 groups were approximately 106 % and 7 %, respectively as compared to control (n = 8, Fig. 3c). The AUC_{0.5h} (Fig. 3b) and AUC_{3-4h} (Fig. 3c) value of the SENS+vehicle group was significantly higher than that of control group which was attenuated by treatment with CVT-6883 in sensitized group (SENS+CVT-6883) only in AUC_{3-4h} (p < 0.05, ANOVA) as shown in Fig. 3 (c).

**Effect of Aerosolized CVT-6883 and Theophylline on Allergen-induced Increases in the Number of the Inflammatory Cells in BALF**

The effect of CVT-6883 on allergen-induced increases in the number of inflammatory cells in BALF obtained from sensitized mice was determined. As shown in Figure 4 (a, top panel), allergen challenge significantly increased the number of total cells in BALF of sensitized group (SENS+Vehicle) as compared to control group and treatment with either CVT-6883 (aerosol delivery of 6 mg/ml solution for 5 min) or theophylline (THEO, aerosol delivery of 36 mg/ml solution for 5 min) significantly reduced the increases in total cells (n = 6-8; Fig. 4a; p < 0.05, ANOVA).

Similarly, allergen challenge increased the number of eosinophils in BALF of sensitized group (SENS+Vehicle) as compared to control group, and treatment with either CVT-6883 or theophylline significantly reduced the increases in eosinophils (n = 6-8; Fig. 4b; p < 0.05, ANOVA).
In addition, allergen challenge also increased the number of lymphocytes in BALF of sensitized group (SENS+Vehicle) as compared to control group, with only CVT-6883 significantly attenuating the allergen-induced increase in lymphocytes (n = 6-8; Fig. 4c; p < 0.05, ANOVA).

Furthermore, allergen challenge increased the number of macrophages in BALF of sensitized group (SENS+Vehicle) as compared to control group (p< 0.05, ANOVA), treatments either with theophylline or CVT-6883 did not significantly reduce the increased number of macrophage by allergen (p> 0.05, ANOVA). The numbers of macrophages \(10^4\) in control, SENS, SENS+THEO and SENS+CVT-6883 groups were 10.05± 0.89, 19± 3.21, 24± 2 and 19± 2, respectively (n = 6-8).
Discussion

The main objective of this study was to determine the effects of A$_{2B}$ AR antagonist, CVT-6883 on airway reactivity induced by AMP, NECA or allergen as well as allergen-induced infiltration of inflammatory cells in the mice airway. The major findings of this study were that treatment with CVT-6883 attenuated the airway reactivity induced by NECA, AMP or allergen in sensitized mice. In addition, treatment with aerosolized CVT-6883 attenuated the increases in the number of total cells present in BALF, specifically eosinophils and lymphocytes after allergen challenge. When compared with montelukast, CVT-6883 was as effective as montelukast in inhibiting AMP-induced airway reactivity in sensitized mice. Moreover, CVT-6883 showed overall better efficacy in inhibiting allergen-induced influx of inflammatory cells into the lung when compared with theophylline.

The acute effect of inhaled adenosine (or inhaled AMP) on bronchoconstriction is well established in asthmatic subjects (Holgate, 2005). One of the proposed mechanisms of AMP challenge suggests that adenosine, degraded from AMP, interacts with A$_{2B}$ receptors on the “primed” mast cells in the lung with subsequent release of preformed and newly formed mediators. The mediators in turn act on bronchial smooth muscle to cause bronchoconstriction (Holgate, 2005). Although this proposed mechanism seems to explain most of the clinical observations caused by inhalation of AMP, this mechanism remains unproven.

To determine which adenosine receptor subtype(s) are involved in adenosine-induced airway reactivity, several selective adenosine agonists or antagonists have been tested in numerous allergic animal models. Using the allergic mouse model in the current
study, the selective A$_1$ agonist CPA (N6-cyclopentyladenosine) or CVT-510 (2-{6-[(3S)oxolan-3-yl]amino}purin-9-yl)(2S,4S,3R)-5-(hydroxymethyl)oxolane-3,4-diol), or selective A$_2$A agonists CGS-21680 (2-(p-(2-carboxyethyl)-phenethylamino)-5'-N-ethylcarboxamido adenosine) or CVT-3146 (1-{9-[(4S,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide) do not increase airway reactivity due to allergen challenge (data not shown). In contrast, the nonselective agonist NECA increases airway reactivity and the A$_3$ agonist Cl-IB-MECA (N6-(3-iodo-benzyl)-2-chloro-adenosine-5'-N-methyluronamide) also increases airway reactivity albeit to a less extent than NECA (Fan et al, 2003 and unpublished data). The effect of NECA is partially blocked by enprofylline, a relative selective A$_{2B}$ antagonist, or MRS 1523, a selective A$_3$ antagonist. In allergic guinea pig model, it was reported that A$_1$ agonist CPA induces airway obstruction by a neuronal-dependent mechanism whereas A$_{2A}$ agonist CGS 21680 or A$_3$ agonist IB-MECA has no effect (Keir et al, 2006). Interestingly, it was also reported that A$_3$ agonist IB-MECA could contract sensitized guinea pig trachea (Martin and Broadley, 2002). In allergic rabbit model, adenosine-induced contractions of tracheal and bronchial smooth muscles are mainly due to the activation of A$_1$ receptors on rabbit smooth muscle (Ali et al, 1994). In this model, A$_1$ antagonist L-97-1 seems to be effective in blocking adenosine-induced bronchoconstriction (Obiefuna et al, 2005). Obviously, different receptor subtypes have been implicated in airway reactivity depending on the animal models.

In the present study, similar to human, AMP challenge caused increase in airway reactivity in mice that were sensitized and challenged by ragweed but not in sham-sensitized/challenged mice. In addition, the AMP-induced airway reactivity was
completed inhibited by treatment of CVT-6883. To our knowledge, this is the first report that a selective $\text{A}_2\text{B}$ antagonist is able to attenuate the AMP-induced airway reactivity in an animal model. The result supports the proposed mechanism that $\text{A}_2\text{B}$ receptors might be involved in mediating the airway response induced by AMP challenge. However, due to the differences in airway physiology between human and animal models, one needs to be cautious in extrapolation of these findings to humans.

Because AMP-induced bronchoconstriction has been hypothesized to be an indirect mechanism by releasing contractile mediators, many clinical studies have focused on identifying potential mediators (Holgate et al, 2005). It has been shown that AMP-induced acute bronchoconstriction can be inhibited by selective histamine H1 antagonist (terfenadine or astemizole), leukotriene receptor antagonist (montelukast) and inhibitors of cyclooxygenase 1 and 2 (indomethacin or flurbiprofen). In addition, AMP challenge leads to increased levels of several contractile mediators including histamine, PGD2 in asthmatic airways and leukotriene in breath condensate (Polosa et al, 1995; Bucchioni et al, 2004). In the present studies, CVT-6883 and montelukast attenuated AMP-induced airway reactivity to a similar degree, supporting the hypothesis that AMP-induced airway reactivity is mediated mainly via cysteiny1 leukotrienes in this animal model.

In asthmatics, besides the acute bronchoconstriction, inhaled allergen induces a prolonged late phase reaction due to the accumulation of cytokines and chemokines generated by resident inflammatory cells (e.g., mast cells, macrophage, epithelial cells) and recruited inflammatory cells (e.g., lymphocytes and eosinophils) (Busse and Lemanske, 2001). In the present study, CVT-6883 inhibited the late-phase allergen-
induced airway reactivity and inhibited the allergen-induced increase in eosinophils and lymphocytes. This result is consistent with early publications suggesting that A2B receptors may play important role in amplifying the inflammatory responses in the airway. It has been shown that activation of A2B receptors in human mast cells (HMC-1) leads to an increase in the release of IL-4 and IL-13 (Ryzhov et al 2004). IL-4 and IL-13 are well-known Th2 cytokines that promote differentiation of Th2 cells and activate B-cells to synthesize and release IgE. In addition, activation of A2B receptors in bronchial epithelial cells leads to the generation of IL-19, which in turn activates monocytes to release TNFα (Zhong et al, 2006). Similarly, activation of A2B receptors in bronchial smooth muscle cells and lung fibroblasts leads to the generations of numerous inflammatory cytokines and chemokines such as IL-6, MCP-1 and IL-8 (Zhong et al, 2004; Zhong et al, 2005). It has been shown recently that A2B receptor activation can lead to increase in IL-10 production in lipopolysaccharide-stimulated murine macrophages (Nemeth et al, 2005). Our data suggest that the release of cytokines like IL-10 from macrophages may not be modulated by antagonism of A2B receptors after allergen challenge. Allergen and lipopolysaccharide may modulate A2B receptors by different mechanisms thereby leading to different inflammatory responses. Altogether, these results suggest that antagonism of A2B receptors potentially could inhibit the allergen-induced activation of inflammatory cells and thereby inhibit the late-phase allergen responses.

The functional relevance of A3 adenosine receptors in the pathogenesis of asthma remains controversial mostly due to species differences. In rodents, A3 adenosine receptors have been shown to play an important role in mast cell degranulation,
bronchoconstriction, eosinophilia and mucus production (Tilley et al, 2003; Fan et al, 2003; Ramkumar et al, 1993). A study in human asthmatics showed an increase in the expression of A₃ ARs in lung biopsies of patients with asthma, which were mostly located on eosinophils. In addition, it was suggested that A₃ ARs were also involved in inhibition of chemotaxis (Walker et al, 1997).

On the other hand, animal and human studies suggest an important role for A₂B AR in mediating airway reactivity and inflammatory responses in the lung (Holgate, 2005; Polosa, 2002). Expression of adenosine A₂B receptors has been found in bronchial epithelium (Clancy et al, 1999), in cultured human airway smooth muscle (Mundell et al, 2001), in human mast cells (Marquardt et al, 1994), monocytes (Zhang et al, 2005) and fibroblasts (Zhong et al, 2005). The NECA-induced increase in airway reactivity was partially blocked by enprofylline, a relatively selective A₂B antagonist (Fan et al, 2003). Human B-lymphocytes co-cultured with NECA-stimulated mast cells produced high level of IgE, as compared with B-lymphocytes co-cultured with non-stimulated mast cells (Ryzhov et al, 2004). These observations suggest a more specific role for A₂B receptors in allergic asthma.

In summary, our findings provide in vivo evidence that antagonism of adenosine A₂B receptors by CVT-6883 leads to inhibition of airway inflammation and airway reactivity induced by allergen or AMP, thus corroborating the earlier evidence for the role of A₂B receptors in the pathophysiology of asthma.
Acknowledgements

We would like to thank Jeff Zablocki, Rao Kalla, Elfatih Elzein, Venkata Palla, Thao Perry, and Xiaofen Li for chemical synthesis of CVT-6883; Ming Yang, Tenning Maa, and Arthur Gimbel for their help in the in vitro characterization of CVT-6883.
References


Legends for Figures:

Figure 1. Effect of CVT-6883 on NECA-induced increases in Penh in sensitized mice. Mice were treated with vehicle (SENS+Vehicle), or three doses of CVT-6883 (SENS+CVT-6883). Data shown are mean ± SEM (n = 5-6). The Penh values in the vehicle-treated group were significantly different from CVT-6883-treated groups (p<0.05; ANOVA), except there was no statistical difference between vehicle and CVT-6883 (2.5 mg/kg) treated groups at NECA concentration of 93.8 µg/ml.

Figure 2. Effect of CVT-6883 and montelukast on AMP-induced increases in Penh in control and sensitized (SENS) mice. Data represent the concentration-response relationship to aerosolized AMP in (a) control (Control, left panel), and (b) sensitized (SENS, right panel) mice treated with vehicle, CVT-6883 (1 mg/kg, i.p.) or montelukast (1 mg/kg, i.p.). Data shown are mean± SEM (n = 7-8). The AMP-induced Penh increases in the SEN+vehicle group was significantly higher than Penh increases in SEN+CVT-6883 group (12 and 24 mg/ml) or SEN+montelukast group (6, 12, and 24 mg/ml) (p < 0.05, ANOVA).

Figure 3. Effect of CVT-6883 on late allergic response in control and sensitized (SENS) mice. Shown is the time course of allergen-induced change in Penh in control mice (Control), or sensitized mice treated with vehicle (SENS+Vehicle) or CVT-6883 (SENS+CVT-6883, 1 mg/kg, i.p.). On day 14, mice were challenged with ragweed (by aerosol) for 10 min and monitored for 5 h. (a) Top Panel: Penh-time curves of all groups (b) Bottom left panel: Area under Penh-time curves (AUC) were calculated for the entire
five hours of recording (AUC0-5h) and (c) for the late allergic response (LAR) that occurred between 3-4 hrs after allergen challenge (AUC3-4h). Data are expressed as the mean ± SEM (n=8) *p<0.05 as compared to control; #p<0.05 as compared to SENS+Vehicle group (ANOVA).

**Figure 4.** Effect of treatment with CVT-6883 (6 mg/ml, aerosol for 5 min) or theophylline (THEO, 36 mg/ml, aerosol for 5 min) on the number of inflammatory cells in BALF. On day 14, mice were challenged with ragweed (by aerosol) for 10 min and allergen-induced infiltration of (a) total cells, (b) eosinophils and (c) lymphocytes was assessed after 5h in bronchoalveolar lavage fluid (BALF) of control mice (Control), or sensitized mice treated with vehicle (SENS+Vehicle), CVT-6883 (SENS+CVT-6883) or theophylline (SENS+THEO). Data shown are mean ± SEM/ml (n = 6-8) of total and differential cell counts in BALF. * p < 0.05 as compared to control mice; # p < 0.05 as compared to SENS+Vehicle group (ANOVA).
Fig. 1
Fig. 2

(a)

Fig. 2
Fig. 2b

**SENS+Vehicle**

**SENS+CVT-6883**

**SENS+Montelukast**

**AMP (mg/ml)**

**Penh (% of nebulization vehicle)**

- 6.0
- 12.0
- 24.0

Fig. 2
Fig. 3

(a)

Time (min)

Penh

Control
SENS+Vehicle
SENS+CVT-6883
Fig. 3

- **Control**
- **SENS+Vehicle**
- **SENS+CVT-6883**

**AUC 0-5 h**

(b)
Fig. 3

AUC 3-4 h

- Control
- SEN+Vehicle
- SEN+CVT-6883

(c)
**Fig. 4**

![Bar chart showing total cell number (x10^4) for different treatments.](chart)

- Control
- SENS+Vehicle
- SENS+THEO
- SENS+CVT-6883

(a)

This article has not been copyedited and formatted. The final version may differ from this version.
Fig. 4 (b)

Eosinophils ($\times 10^4$)

- Control
- SENS+Vehicle
- SENS+THEO
- SENS+CVT-6883

* #
Fig. 4

(c)

Lymphocytes (x10^4)

- Control
- SENS+Vehicle
- SENS+THEO
- SENS+CVT-6883

*  
#